Edition:
India

OPKO Health Inc (OPK.OQ)

OPK.OQ on NASDAQ Stock Exchange Global Select Market

3.59USD
19 Oct 2018
Change (% chg)

$-0.08 (-2.18%)
Prev Close
$3.67
Open
$3.63
Day's High
$3.82
Day's Low
$3.55
Volume
898,851
Avg. Vol
1,675,826
52-wk High
$6.99
52-wk Low
$2.66

Latest Key Developments (Source: Significant Developments)

Phillip Frost Issues Statement Regarding SEC Lawsuit
Saturday, 15 Sep 2018 

Sept 14 (Reuters) - Phillip Frost::PHILLIP FROST ISSUES STATEMENT REGARDING SEC LAWSUIT.PHILLIP FROST - INVESTED IN 2 OF ENTITIES IDENTIFIED IN SEC COMPLAINT; REMAIN "SIGNIFICANT LONG-TERM" SHAREHOLDER IN BOTH COS.PHILLIP FROST SAYS "STUNNED BY SEC'S LAWSUIT AND DENY ALLEGATIONS IT CONTAINS AGAINST ME".  Full Article

Opko Comments On SEC Complaint
Saturday, 8 Sep 2018 

Sept 7 (Reuters) - OPKO Health Inc ::OPKO COMMENTS ON SEC COMPLAINT.SAYS "SEC FAILED TO PROVIDE NOTICE OF ITS INTENT TO SUE PRIOR TO FILING COMPLAINT".SAYS SEC COMPLAINT "CONTAINS SERIOUS FACTUAL INACCURACIES".  Full Article

OPKO Health Q2 Loss Per Share $0.01
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - OPKO Health Inc ::OPKO HEALTH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.01.Q2 REVENUE $263.7 MILLION VERSUS I/B/E/S VIEW $261.7 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.07 -- THOMSON REUTERS I/B/E/S.  Full Article

OPKO Health Inc Says Intends To Remain On Tel Aviv Stock Exchange
Saturday, 28 Apr 2018 

April 27 (Reuters) - OPKO Health Inc ::OPKO HEALTH INC - INTENDS TO REMAIN ON TEL AVIV STOCK EXCHANGE AND WITHDRAW ITS REQUEST TO VOLUNTARILY DELIST ITS COMMON STOCK FROM TASE.OPKO HEALTH TO REMAIN ON TEL AVIV STOCK EXCHANGE.OPKO HEALTH - HAVE SPOKEN WITH CO'S ISRAEL-BASED INVESTORS; THEY EXPRESSED DESIRE CO CONTINUE PRESENCE ON TASE AND URGED CO TO RECONSIDER DECISION.  Full Article

Opko Health qtrly loss per share $0.08‍​
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Opko Health Inc ::Opko Health reports 2017 third quarter highlights and financial results.Q3 revenue $263.5 million versus I/B/E/S view $319.4 million.Opko Health Inc qtrly loss per share $0.08‍​.  Full Article

OPKO Health submits premarket approval application with FDA for PSA test
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - OPKO Health Inc :OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform.OPKO Health Inc - ‍filing contains clinical data from company's 864-patient total psa clinical study​.OPKO Health Inc - ‍OPKO expects to initiate clinical validation studies and to file a 510(k) application for a Claros 1 testosterone test in 2018​.OPKO Health - working to add additional tests for vitamin D, infectious diseases, cardiology, women's health, companion diagnostics to Claros 1 menu​.  Full Article

Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Xenetic Biosciences :Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc.Xenetic Biosciences Inc - ‍Xenetic to receive one-time payment of $7.5 million and single digit royalty payments based upon net sales​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Opko Health Inc :Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan.Opko Health Inc - ‍Under terms of agreement, JT will make an upfront payment to Opko of $6 million.Opko Health says unit ‍eirgen Pharma entered into an exclusive agreement with Japan Tobacco for development and commercialization in Japan of Rayaldee​.Opko Health - As per agrement, co eligible to receive up to additional $31 million in development & regulatory milestones & $75 million in sales based milestones​.Opko Health Inc - JT will make​ another ‍$6 million payment to co upon initiation of Opko's planned phase 2 study of Rayaldee in U.S. dialysis patients.  Full Article

Xenetic Biosciences reports Q2 loss per share $0.34
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Xenetic Biosciences Inc :Xenetic biosciences reports 2017 second quarter financial results and provides business update.Qtrly loss per share $0.34.  Full Article

BRIEF-Opko Health Reports Q1 Loss Per Share Of $0.08

* Q1 REVENUE $254.9 MILLION VERSUS I/B/E/S VIEW $236.9 MILLION